• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

New Delhi, Dec. 6 Jubilant Biosys will be developing a small molecule drug candidate to treat a novel metabolic disorders target for the US-based Forest Laboratories Holdings.

The subsidiary of Jubilant Organosys Ltd will receive payments for research, development and commercialisation milestones from its US partner for its drug development work. Forest, which will own the worldwide commercial rights to the drug, will be responsible for pre-clinical and clinical development of the molecule. The two companies announced their collaboration on Thursday.

“This collaboration leverages the innovation capabilities of Jubilant Biosys in pharmaceutical discovery and preclinical development, as well as combining these strengths with Forest Lab to deliver new products with cost effective efficiency that will help patients around the world,” said the company’s management in a statement.

More Stories on : Alliances & Joint Ventures | Pharmaceuticals | Research & Development

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
‘ONGC to shut down 2 facilities off Mumbai’

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line